BR112023022195A2 - Novas composições e métodos de n,n-dimetiltriptamina - Google Patents
Novas composições e métodos de n,n-dimetiltriptaminaInfo
- Publication number
- BR112023022195A2 BR112023022195A2 BR112023022195A BR112023022195A BR112023022195A2 BR 112023022195 A2 BR112023022195 A2 BR 112023022195A2 BR 112023022195 A BR112023022195 A BR 112023022195A BR 112023022195 A BR112023022195 A BR 112023022195A BR 112023022195 A2 BR112023022195 A2 BR 112023022195A2
- Authority
- BR
- Brazil
- Prior art keywords
- dimethyltryptamine
- dmt
- compositions
- new
- methods
- Prior art date
Links
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179679P | 2021-04-26 | 2021-04-26 | |
| PCT/US2022/026396 WO2022232179A1 (en) | 2021-04-26 | 2022-04-26 | Novel n,n-dimethyltryptamine compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022195A2 true BR112023022195A2 (pt) | 2024-01-16 |
Family
ID=83694712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022195A BR112023022195A2 (pt) | 2021-04-26 | 2022-04-26 | Novas composições e métodos de n,n-dimetiltriptamina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11602521B2 (https=) |
| EP (1) | EP4329879A4 (https=) |
| JP (1) | JP2024517738A (https=) |
| KR (1) | KR20240000516A (https=) |
| CN (1) | CN117320711A (https=) |
| AU (1) | AU2022267240A1 (https=) |
| BR (1) | BR112023022195A2 (https=) |
| CA (1) | CA3216889A1 (https=) |
| CL (1) | CL2023003191A1 (https=) |
| IL (1) | IL308074A (https=) |
| MX (1) | MX2023012651A (https=) |
| WO (1) | WO2022232179A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| CA3218110A1 (en) * | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| AU2022287974A1 (en) | 2021-06-09 | 2024-01-04 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023186837A1 (en) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Treatment of postnatal depression |
| CA3267555A1 (en) * | 2022-10-26 | 2024-05-02 | Atai Therapeutics, Inc. | Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use |
| DK202330319A1 (en) * | 2023-11-07 | 2025-05-27 | Fertin Pharma As | An adhesive oral disc for sustained release of cannabinoids |
| CN121194779A (zh) | 2023-03-31 | 2025-12-23 | 赛本英国有限公司 | 包含单胺抗抑郁剂和短效致幻剂的组合 |
| WO2025054397A1 (en) * | 2023-09-08 | 2025-03-13 | Atai Therapeutics, Inc. | Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof |
| WO2025076151A1 (en) * | 2023-10-02 | 2025-04-10 | Atai Therapeutics, Inc. | N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220079881A1 (en) | 2016-03-03 | 2022-03-17 | Ctt Pharma Inc. | Orally Administrable Composition |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| HUE069534T2 (hu) * | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| US20220304980A1 (en) | 2019-07-04 | 2022-09-29 | SW Holdings, Inc | Metered dosing compositions and methods of use of psychedelic compounds |
| US20210015738A1 (en) * | 2019-07-17 | 2021-01-21 | Concept Matrix Solutions | Oral dissolvable film containing psychedelic compound |
| WO2021138564A1 (en) * | 2019-12-31 | 2021-07-08 | Cure Pharmaceutical Holding Corp. | Oral dissolvable film and method of manufacturing and using the same |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP4167992A1 (en) * | 2020-06-22 | 2023-04-26 | University of Zürich | Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy |
| EP4192451A4 (en) * | 2020-08-05 | 2024-08-14 | Universitätsspital Basel | METHOD OF ADMINISTERING INTRAVENOUS DMT FOR DMT-ASSISTED PSYCHOTHERAPY |
| AU2021343525A1 (en) | 2020-09-20 | 2023-05-18 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
-
2022
- 2022-04-26 JP JP2023566493A patent/JP2024517738A/ja active Pending
- 2022-04-26 KR KR1020237038175A patent/KR20240000516A/ko active Pending
- 2022-04-26 WO PCT/US2022/026396 patent/WO2022232179A1/en not_active Ceased
- 2022-04-26 EP EP22796577.9A patent/EP4329879A4/en active Pending
- 2022-04-26 MX MX2023012651A patent/MX2023012651A/es unknown
- 2022-04-26 IL IL308074A patent/IL308074A/en unknown
- 2022-04-26 US US17/730,013 patent/US11602521B2/en active Active
- 2022-04-26 CN CN202280031363.4A patent/CN117320711A/zh active Pending
- 2022-04-26 BR BR112023022195A patent/BR112023022195A2/pt unknown
- 2022-04-26 CA CA3216889A patent/CA3216889A1/en active Pending
- 2022-04-26 AU AU2022267240A patent/AU2022267240A1/en active Pending
-
2023
- 2023-10-25 CL CL2023003191A patent/CL2023003191A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL308074A (en) | 2023-12-01 |
| WO2022232179A9 (en) | 2023-07-13 |
| WO2022232179A1 (en) | 2022-11-03 |
| KR20240000516A (ko) | 2024-01-02 |
| CA3216889A1 (en) | 2022-11-03 |
| MX2023012651A (es) | 2023-11-06 |
| US20220339139A1 (en) | 2022-10-27 |
| EP4329879A1 (en) | 2024-03-06 |
| AU2022267240A1 (en) | 2023-11-23 |
| US11602521B2 (en) | 2023-03-14 |
| CN117320711A (zh) | 2023-12-29 |
| JP2024517738A (ja) | 2024-04-23 |
| EP4329879A4 (en) | 2025-04-09 |
| CL2023003191A1 (es) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023022195A2 (pt) | Novas composições e métodos de n,n-dimetiltriptamina | |
| JP5030553B2 (ja) | ドライマウスおよび／または唾液分泌障害を処置するための医薬 | |
| Scutariu et al. | Importance of dental maxillofacial aesthetics in dental therapy | |
| Yang et al. | Sihler-stain study of buccal nerve distribution and its clinical implications | |
| Paraskevas et al. | Thromboangiitis obliterans (Buerger’s disease): searching for a therapeutic strategy | |
| Iorio-Siciliano et al. | Treatment of gingival recessions using coronally advanced flap and connective tissue graft: a long-term retrospective analysis | |
| Amaliya et al. | Periodontal disease: a rise in prevalence in military troops penyakit periodontal | |
| Olsson et al. | Occlusal interferences in orthodontic patients before and after treatment, and in subjects with minor orthodontic treatment need | |
| Kandasamy et al. | Removal of maxillary teeth with buccal 4% articaine without using palatal anesthesia—a comparative double blind study | |
| Friberg | Brånemark system implants and rare disorders: a report of six cases. | |
| Khademi et al. | Association between psychological factors and pain perception in patients with symptomatic irreversible pulpitis during endodontic treatment | |
| Hashim et al. | The role of acupuncture in the treatment of prosthodontic patients with a gagging reflex | |
| Hinsie | The treatment of schizophrenia: A survey of the literature | |
| SUNDAR et al. | Effectiveness of the Greater Palatine Nerve Block for Anaesthetising Anterior Palate: A Prospective Study. | |
| Kikuchi et al. | Effects of apremilast on pustulotic arthro‐osteitis in a real‐world setting: Report of five cases. | |
| Puranik et al. | Dental patient’s knowledge and awareness regarding effects of smoking on oral health among smokers and nonsmokers: a comparative study | |
| Harris | Trigeminal neuralgia at exceptionally early age | |
| IT201900001081A1 (it) | Composizione per il trattamento delle parodontiti e la rigenerazione della papilla interdentale | |
| RU2532399C2 (ru) | Способ лечения пародонтита | |
| IF0220006 | Evaluation of the efficacy of Local buffered local anesthetic in Extraction of infected teeth–Randomized double blind study | |
| Sluder | A phenol (carbolic acid) injection treatment for sphenopalatine ganglion neuralgia | |
| Tormos et al. | Sinus Augmentation and Simultaneous Implant Placement Success: Pilot Study (2008–2011) | |
| Diz Dios et al. | Supportive and palliative care for patients with oral cancer | |
| Farkas et al. | Quantitative assessment of the morphology of the pig's head used as a model in surgical experimentation part 2: results of measurements | |
| Avazbek et al. | MODERN APPROACHES TO THE TREATMENT OF CHRONIC GENERALIZED PERIODONTITIS USING LASER THERAPY |